PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy

Immunotherapy with PD-1/PD-L1-blocking antibodies is clinically effective for several tumor types, but the mechanism is not fully understood. PD-L1 expression on tumor biopsies is generally regarded as an inclusion criterion for this cancer therapy. Here, we describe the PD-L1-blocking therapeutic r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Kleinovink, Jan Willem, Marijt, Koen A., Schoonderwoerd, Mark J. A., van Hall, Thorbald, Ossendorp, Ferry, Fransen, Marieke F.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2017
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5414865/
https://ncbi.nlm.nih.gov/pubmed/28507803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1294299
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados